HDL functionality in diabetes mellitus: Potential importance of glycation

Clinical Lipidology

Volumn 7, Issue 5, 2012, Pages 561-578

  Younis, Nahla N ^a   Durrington, Paul N ^b  

^a Zagazig University   (Egypt)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

cholesteryl ester transfer protein; diabetes mellitus; dysfunctional HDL; glycation; HDL; lecithin:cholesterol acyl transferase; PON 1

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANACETRAPIB; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A1 MIMETIC PEPTIDE; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CSL 111; DALCETRAPIB; ETC 216; EVACETRAPIB; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN MIMETIC; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; METFORMIN; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PLACEBO; PRAVASTATIN; RECONSTITUTED HIGH DENSITY LIPOPROTEIN; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CHEMICAL COMPOSITION; CHEMICAL MODIFICATION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG DOSE TITRATION; DYSLIPIDEMIA; GLYCATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 84869382029     PISSN: 17584299     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.12.60     Document Type: Review

References (150)

1. Vessby B, Gustafson S, Chapman MJ, Hellsing K, Lithell H. Lipoprotein composition of human suction-blister interstitial fluid. J. Lipid Res. 28(6), 629-641 (1987). (Pubitemid 17085962)
2. Mackness MI, Mackness B, Arrol S, Wood G, Bhatnagar D, Durrington PN. Presence of paraoxonase in human interstitial fluid. FEBS Lett. 416(3), 377-380 (1997). (Pubitemid 27475401)
3. Durrington PN. Hyperlipidaemia: Diagnosis and Management (3rd Edition). Hodder Arnold, London, UK (2007).
4. Di Angelantonio E, Sarwar N, Perry P et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302(18), 1993-2000 (2009).
5. Schmitz G, Bruning T, Williamson E, Nowicka G. The role of HDL in reverse cholesterol transport and its disturbances in Tangier disease and HDL deficiency with xanthomas. Eur. Heart J. 11(Suppl. E), 197-211 (1990). (Pubitemid 20287958)
6. Rosenson RS, Brewer HB Jr, Davidson WS et al. Cholesterol efflux and atheroprotection: Advancing the concept of reverse cholesterol transport. Circulation 125(15), 1905-1919 (2012).
7. Mackness MI, Abbott C, Arrol S, Durrington PN. The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem. J. 294(Pt 3), 829-834 (1993). (Pubitemid 23286573)
8. Navab M, Yu R, Gharavi N et al. High-density lipoprotein: Antioxidant and anti-inflammatory properties. Curr. Atheroscler. Rep. 9(3), 244-248 (2007). (Pubitemid 47629072)
9. Murphy AJ, Chin-Dusting JP, Sviridov D, Woollard KJ. The anti inflammatory effects of high density lipoproteins. Curr. Med. Chem. 16(6), 667-675 (2009).
10. Patel S, Drew BG, Nakhla S et al. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with Type 2 diabetes. J. Am. Coll. Cardiol. 53(11), 962-971 (2009).
11. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ. Res. 98(11), 1352-1364 (2006). (Pubitemid 43948059)
12. Nofer JR, Levkau B, Wolinska I et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J. Biol. Chem. 276(37), 34480-34485 (2001).
13. Kontush A, Therond P, Zerrad A et al. Preferential sphingosine-1- phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: Relevance to antiapoptotic and antioxidative activities. Arterioscler. Thromb. Vasc. Biol. 27(8), 1843-1849 (2007). (Pubitemid 47207181)
14. Ma J, Liao XL, Lou B, Wu MP. Role of apolipoprotein A-I in protecting against endotoxin toxicity. Acta Biochim. Biophys. Sin. (Shanghai) 36(6), 419-424 (2004). (Pubitemid 39091573)
15. Nofer JR, van der Giet M, Tolle M et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest. 113(4), 569-581 (2004). (Pubitemid 38542506)
16. Lesnik P, Chapman MJ. A new dimension in the vasculoprotective function of HDL: Progenitor-mediated endothelium repair. Arterioscler. Thromb. Vasc. Biol. 26(5), 965-967 (2006). (Pubitemid 43732099)
17. Mineo C, Shaul PW. HDL stimulation of endothelial nitric oxide synthase: A novel mechanism of HDL action. Trends Cardiovasc. Med. 13(6), 226-231 (2003). (Pubitemid 36960169)
18. Pan B, Ren H, Ma Y et al. HDL of patients with Type 2 diabetes mellitus elevates the capability of promoting migration and invasion of breast cancer cells. Int. J. Cancer 131(1), 70-82 (2011).
19. Libby P, Miao P, Ordovas JM, Schaefer EJ. Lipoproteins increase growth of mitogenstimulated arterial smooth muscle cells. J. Cell. Physiol. 124(1), 1-8 (1985). (Pubitemid 15042631)
20. Chen JK, Hoshi H, Mcclure DB, McKeehan WL. Role of lipoproteins in growth of human adult arterial endothelial and smooth muscle cells in low lipoprotein-deficient serum. J. Cell. Physiol. 129(2), 207-214 (1986). (Pubitemid 17179564)
21. Cuthbert JA, Lipsky PE. Lipoproteins may provide fatty acids necessary for human lymphocyte proliferation by both low density lipoprotein receptor-dependent and -independent mechanisms. J. Biol. Chem. 264(23), 13468-13474 (1989). (Pubitemid 19198424)
22. Soran H, Hama S, Yadav R, Durrington PN. HDL functionality. Curr. Opin. Lipidol. 23(4), 353-366 (2012).
23. Taskinen MR. Diabetic dyslipidemia: From basic research to clinical practice. Diabetologia 46(6), 733-749 (2003).
24. Drew BG, Duffy SJ, Formosa MF et al. High-density lipoprotein modulates glucose metabolism in patients with Type 2 diabetes mellitus. Circulation 119(15), 2103-2111 (2009).
25. Fryirs MA, Barter PJ, Appavoo M et al. Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler. Thromb. Vasc. Biol. 30(8), 1642-1648 (2010).
26. Barter PJ, Rye KA, Tardif JC et al. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation 124(5), 555-562 (2011).
27. Zhong S, Sharp DS, Grove JS et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J. Clin. Invest. 97(12), 2917-2923 (1996). (Pubitemid 26197108)
28. Koseki M, Matsuyama A, Nakatani K et al. Impaired insulin secretion in four Tangier disease patients with ABCA1 mutations. J. Atheroscler. Thromb. 16(3), 292-296 (2009).
29. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RB Sr. Prediction of incident diabetes mellitus in middle-aged adults: The Framingham Offspring Study. Arch. Intern. Med. 167(10), 1068-1074 (2007). (Pubitemid 46835795)
30. Onat A, Hergenc G, Bulur S, Ugur M, Kucukdurmaz Z, Can G. The paradox of high apolipoprotein A-I levels independently predicting incident Type-2 diabetes among Turks. Int. J. Cardiol. 142(1), 72-79 (2010).
31. Onat A, Hergenc G. Low-grade inflammation, and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk. Metabolism 60(4), 499-512 (2011).
32. Onat A, Can G, Cicek G, Ayhan E, Dogan Y, Kaya H. Fasting, non-fasting glucose and HDL dysfunction in risk of pre-diabetes, diabetes, and coronary disease in non-diabetic adults. Acta Diabetol. doi:10.1007/s00592-011-0313-x (2011) (Epub ahead of print).
33. Asztalos BF, Tani M, Schaefer EJ. Metabolic and functional relevance of HDL subspecies. Curr. Opin. Lipidol. 22(3), 176-185 (2011).
34. Riemens S, van Tol A, Sluiter W, Dullaart R. Elevated plasma cholesteryl ester transfer in NIDDM: Relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis 140(1), 71-79 (1998). (Pubitemid 28378456)
35. Rashid S, Watanabe T, Sakaue T, Lewis GF. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: The combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin. Biochem. 36(6), 421-429 (2003). (Pubitemid 37083556)
36. Adiels M, Olofsson SO, Taskinen MR, Boren J. Diabetic dyslipidemia. Curr. Opin. Lipidol. 17(3), 238-246 (2006).
37. Yost TJ, Froyd KK, Jensen DR, Eckel RH. Change in skeletal muscle lipoprotein lipase activity in response to insulin/glucose in non-insulin-dependent diabetes mellitus. Metabolism 44(6), 786-790 (1995).
38. Bhatnagar D, Durrington PN, Kumar S, Mackness MI, Dean J, Boulton AJ. Effect of treatment with a hydroxymethylglutaryl coenzyme A reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester transfer activity in patients with NIDDM. Diabetes 44(4), 460-465 (1995).
39. Bhatnagar D, Durrington PN, Kumar S, Mackness MI, Boulton AJ. Plasma lipoprotein composition and cholesteryl ester transfer from high density lipoproteins to very low density and low density lipoproteins in patients with non-insulin-dependent diabetes mellitus. Diabet. Med. 13(2), 139-144 (1996). (Pubitemid 26074291)
40. Rashid S, Barrett PH, Uffelman KD, Watanabe T, Adeli K, Lewis GF. Lipolytically modified triglyceride-enriched HDLs are rapidly cleared from the circulation. Arterioscler. Thromb. Vasc. Biol. 22(3), 483-487 (2002). (Pubitemid 34218758)
41. Rashid S, Trinh DK, Uffelman KD, Cohn JS, Rader DJ, Lewis GF. Expression of human hepatic lipase in the rabbit model preferentially enhances the clearance of triglyceride-enriched versus native highdensity lipoprotein apolipoprotein A-I. Circulation 107(24), 3066-3072 (2003). (Pubitemid 36758981)
42. Baynes C, Henderson AD, Anyaoku V et al. The role of insulin insensitivity and hepatic lipase in the dyslipidemia of Type 2 diabetes. Diabet. Med. 8(6), 560-566 (1991).
43. Bagdade JD, Knight-Gibson C, Simpson N, Gerkin R, Alaupovic P, Reardon C. CETP-mediated cholesteryl ester enrichment of apoB subclasses in Type 1 diabetes. Eur. J. Clin. Invest. 42(7), 709-716 (2011).
44. Kumon Y, Suehiro T, Itahara T, Ikeda Y, Hashimoto K. Serum amyloid A protein in patients with non-insulin-dependent diabetes mellitus. Clin. Biochem. 27(6), 469-473 (1994).
45. Urieli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr. Opin Hematol. 7(1), 64-69 (2000). (Pubitemid 30007690)
46. Mackness B, Durrington PN, Abuashia B, Boulton AJ, Mackness MI. Low paraoxonase activity in Type II diabetes mellitus complicated by retinopathy. Clin. Sci. (Lond.) 98(3), 355-363 (2000). (Pubitemid 30145243)
47. Mackness B, Durrington PN, Boulton AJ, Hine D, Mackness MI. Serum paraoxonase activity in patients with Type 1 diabetes compared with healthy controls. Eur. J. Clin. Invest. 32(4), 259-264 (2002). (Pubitemid 36216591)
48. Mackness B, Mackness MI, Arrol S et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 139(2), 341-349 (1998). (Pubitemid 28361819)
49. Zhou H, Tan KC, Shiu SW, Wong Y. Increased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy. Nephrol. Dial. Transplant. 23(3), 927-933 (2008). (Pubitemid 351767544)
50. Hoang A, Murphy AJ, Coughlan MT et al. Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. Diabetologia 50(8), 1770-1779 (2007). (Pubitemid 47036662)
51. Durrington PN. Serum high density lipoprotein cholesterol in diabetes mellitus: An analysis of factors which influence its concentration. Clin. Chim. Acta 104(1), 11-23 (1980). (Pubitemid 10118413)
52. Durrington PN. Serum high density lipoprotein cholesterol subfractions in Type I (insulin-dependent) diabetes mellitus. Clin. Chim. Acta 120(1), 21-28 (1982). (Pubitemid 12192290)
53. Winocour PH, Durrington PN, Bhatnagar D et al. A cross-sectional evaluation of cardiovascular risk factors in coronary heart disease associated with Type 1 (insulindependent) diabetes mellitus. Diabetes Res. Clin. Pract. 18(3), 173-184 (1992). (Pubitemid 23032608)
54. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler. Thromb. Vasc. Biol. 15(11), 1812-1818 (1995).
55. Persegol L, Foissac M, Lagrost L et al. HDL particles from Type 1 diabetic patients are unable to reverse the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia 50(11), 2384-2387 (2007). (Pubitemid 47512411)
56. Hedrick CC, Thorpe SR, Fu MX et al. Glycation impairs high-density lipoprotein function. Diabetologia 43(3), 312-320 (2000). (Pubitemid 30163474)
57. Passarelli M, Shimabukuro AF, Catanozi S et al. Diminished rate of mouse peritoneal macrophage cholesterol efflux is not related to the degree of HDL glycation in diabetes mellitus. Clin. Chim. Acta 301(1-2), 119-134 (2000).
58. Kontush A, Chapman MJ. Why is HDL functionally deficient in Type 2 diabetes? Curr. Diab. Rep. 8(1), 51-59 (2008). (Pubitemid 351384876)
59. Persegol L, Verges B, Foissac M, Gambert P, Duvillard L. Inability of HDL from Type 2 diabetic patients to counteract the inhibitory effect of oxidised LDL on endotheliumdependent vasorelaxation. Diabetologia 49(6), 1380-1386 (2006).
60. Persegol L, Verges B, Gambert P, Duvillard L. Inability of HDL from abdominally obese subjects to counteract the inhibitory effect of oxidized LDL on vasorelaxation. J. Lipid Res. 48(6), 1396-1401 (2007). (Pubitemid 47312042)
61. Tan KC. Reverse cholesterol transport in Type 2 diabetes mellitus. Diabetes Obes. Metab. 11(6), 534-543 (2009).
62. Forcheron F, Cachefo A, Thevenon S, Pinteur C, Beylot M. Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic Type 2 diabetic patients. Diabetes 51(12), 3486-3491 (2002). (Pubitemid 35403454)
63. Zhou H, Tan KC, Shiu SW, Wong Y. Determinants of leukocyte adenosine triphosphate-binding cassette transporter G1 gene expression in Type 2 diabetes mellitus. Metabolism 57(8), 1135-1140 (2008). (Pubitemid 351978072)
64. Mauldin JP, Nagelin MH, Wojcik AJ et al. Reduced expression of ATP-binding cassette transporter G1 increases cholesterol accumulation in macrophages of patients with Type 2 diabetes mellitus. Circulation 117(21), 2785-2792 (2008). (Pubitemid 351770459)
65. Albrecht C, Simon-Vermot I, Elliott JI, Higgins CF, Johnston DG, Valabhji J. Leukocyte ABCA1 gene expression is associated with fasting glucose concentration in normoglycemic men. Metabolism 53(1), 17-21 (2004). (Pubitemid 38071930)
66. Passarelli M, Tang C, McDonald TO et al. Advanced glycation end product precursors impair ABCA1-dependent cholesterol removal from cells. Diabetes 54(7), 2198-2205 (2005). (Pubitemid 40911284)
67. Isoda K, Folco EJ, Shimizu K, Libby P. AGE-BSA decreases ABCG1 expression and reduces macrophage cholesterol efflux to HDL. Atherosclerosis 192(2), 298-304 (2007). (Pubitemid 46726331)
68. Ohgami N, Nagai R, Miyazaki A et al. Scavenger receptor class B Type I-mediated reverse cholesterol transport is inhibited by advanced glycation end products. J. Biol. Chem. 276(16), 13348-13355 (2001).
69. Uehara Y, Engel T, Li Z et al. Polyunsaturated fatty acids and acetoacetate downregulate the expression of the ATP-binding cassette transporter A1. Diabetes 51(10), 2922-2928 (2002).
70. Mauldin JP, Srinivasan S, Mulya A et al. Reduction in ABCG1 in Type 2 diabetic mice increases macrophage foam cell formation. J. Biol. Chem. 281(30), 21216-21224 (2006). (Pubitemid 44115461)
71. Fournier N, Myara I, Atger V, Moatti N. Reactivity of lecithin-cholesterol acyl transferase (LCAT) towards glycated high-density lipoproteins (HDL). Clin. Chim. Acta 234(1-2), 47-61 (1995).
72. Lemkadem B, Loiseau D, Larcher G, Malthiery Y, Foussard F. Effect of the nonenzymatic glycosylation of high density lipoprotein-3 on the cholesterol ester transfer protein activity. Lipids 34(12), 1281-1286 (1999). (Pubitemid 30044266)
73. Passarelli M, Catanozi S, Nakandakare ER et al. Plasma lipoproteins from patients with poorly controlled diabetes mellitus and "in vitro" glycation of lipoproteins enhance the transfer rate of cholesteryl ester from HDL to apo-B-containing lipoproteins. Diabetologia 40(9), 1085-1093 (1997). (Pubitemid 27381972)
74. Chang CK, Tso TK, Snook JT, Huang YS, Lozano RA, Zipf WB. Cholesteryl ester transfer and cholesterol esterification in Type 1 diabetes: Relationships with plasma glucose. Acta Diabetol. 38(1), 37-42 (2001). (Pubitemid 32758292)
75. Ritter MC, Bagdade JD. Contribution of glycaemic control, endogenous lipoproteins and cholesteryl ester transfer protein to accelerated cholesteryl ester transfer in IDDM. Eur. J. Clin. Invest. 24(9), 607-614 (1994). (Pubitemid 24287182)
76. Cooper AD. Hepatic uptake of chylomicron remnants. J. Lipid Res. 38(11), 2173-2192 (1997). (Pubitemid 27495377)
77. Li L, Thompson PA, Kitchens RL. Infection induces a positive acute phase apolipoprotein E response from a negative acute phase gene: Role of hepatic LDL receptors. J. Lipid Res. 49(8), 1782-1793 (2008).
78. Shuvaev VV, Fujii J, Kawasaki Y et al. Glycation of apolipoprotein E impairs its binding to heparin: Identification of the major glycation site. Biochim. Biophys. Acta 1454(3), 296-308 (1999). (Pubitemid 29378377)
79. Sorrentino SA, Besler C, Rohrer L et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with Type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 121(1), 110-122 (2010).
80. Mastorikou M, Mackness B, Liu Y, Mackness M. Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides. Diabet. Med. 25(9), 1049-1055 (2008).
81. Liu D, Ji L, Zhang D et al. Nonenzymatic glycation of high-density lipoprotein impairs its anti-inflammatory effects in innate immunity. Diabetes Metab. Res. Rev. 28(2), 186-195 (2012).
82. Nieuwdorp M, Vergeer M, Bisoendial RJ et al. Reconstituted HDL infusion restores endothelial function in patients with Type 2 diabetes mellitus. Diabetologia 51(6), 1081-1084 (2008).
83. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J. Am. Coll. Cardiol. 27(3), 567-574 (1996). (Pubitemid 26081917)
84. Bosevski M, Borozanov V, Peovska I, Georgievska-Ismail L. Endothelial dysfunction correlates with plasma fibrinogen and HDL cholesterol in Type 2 diabetic patients with coronary artery disease. Bratisl. Lek. Listy 108(7), 297-300 (2007).
85. Giovannucci E, Harlan DM, Archer MC et al. Diabetes and cancer: A consensus report. Diabetes Care 33(7), 1674-1685 (2010).
86. Yang X, So WY, Ma RC et al. Low HDL cholesterol, metformin use, and cancer risk in Type 2 diabetes: The Hong Kong Diabetes Registry. Diabetes Care 34(2), 375-380 (2011).
87. Pan B, Ren H, He Y et al. HDL of patients with Type 2 diabetes mellitus elevates the capability of promoting breast cancer metastasis. Clin. Cancer Res. 18(5), 1246-1256 (2012).
88. Lopez-Saez JB, Martinez-Rubio JA, Alvarez MM et al. Metabolic profile of breast cancer in a population of women in southern Spain. Open Clin. Cancer J. 2, 1-6 (2008).
89. Younis N, Sharma R, Soran H, Charlton-Menys V, Elseweidy M, Durrington PN. Glycation as an atherogenic modification of LDL. Curr. Opin. Lipidol. 19(4), 378-384 (2008).
90. Younis N, Charlton-Menys V, Sharma R, Soran H, Durrington PN. Glycation of LDL in non-diabetic people: Small dense LDL is preferentially glycated both in vivo and in vitro. Atherosclerosis 202(1), 162-168 (2009).
91. Younis NN, Soran H, Sharma R et al. Small-dense LDL and LDL glycation in metabolic syndrome and in statin-treated and non-statin-treated Type 2 diabetes. Diab. Vasc. Dis. Res. 7(4), 289-295 (2010).
92. Rabbani N, Chittari MV, Bodmer CW, Zehnder D, Ceriello A, Thornalley PJ. Increased glycation and oxidative damage to apolipoprotein B100 of LDL cholesterol in patients with Type 2 diabetes and effect of metformin. Diabetes 59(4), 1038-1045 2010).
93. Rabbani N, Godfrey L, Xue M et al. Glycation of LDL by methylglyoxal increases arterial atherogenicity: A possible contributor to increased risk of cardiovascular disease in diabetes. Diabetes 60(7), 1973-1980 (2011).
94. Sima AV, Botez GM, Stancu CS, Manea A, Raicu M, Simionescu M. Effect of irreversibly glycated LDL in human vascular smooth muscle cells: Lipid loading, oxidative and inflammatory stress. J. Cell. Mol. Med. 14(12), 2790-2802 (2010).
95. Sanguinetti SM, Schreier LE, Elbert A, Fasulo V, Ferrari N, Wikinski RL. Detection of structural alterations in LDL isolated from Type 2 diabetic patients: Application of the fructosamine assay to evaluate the extent of LDL glycation. Atherosclerosis 143(1), 213-215 (1999). (Pubitemid 29138721)
96. Pettersson C, Karlsson H, Stahlman M et al. LDL-associated apolipoprotein J and lysozyme are associated with atherogenic properties of LDL found in Type 2 diabetes and the metabolic syndrome. J. Intern. Med. 269(3), 306-321 (2011).
97. Younis NN, Soran H, Sharma R, Charlton-Menys V, Durrington PN. Lipoprotein glycation in atherogenesis. Clin. Lipidol. 4(6), 781-790 (2009).
98. Curtiss LK, Witztum JL. Plasma apolipoproteins AI, AII, B, CI, and E are glucosylated in hyperglycemic diabetic subjects. Diabetes 34(5), 452-461 (1985). (Pubitemid 15083723)
99. Calvo C, Ponsin G, Berthezene F. Characterization of the non enzymatic glycation of high density lipoprotein in diabetic patients. Diabetes Metab. 14(3), 264-269 (1988).
100. Calvo C, Talussot C, Ponsin G, Berthezene F. Non enzymatic glycation of apolipoprotein A-I. Effects on its selfassociation and lipid binding properties. Biochem. Biophys. Res. Commun. 153(3), 1060-1067 (1988).
101. Calvo C, Verdugo C. Association in vivo of glycated apolipoprotein A-I with high density lipoproteins. Eur. J. Clin. Chem. Clin. Biochem. 30(1), 3-5 (1992).
102. de Boer JF, Annema W, Schreurs M et al. Type I diabetes mellitus decreases in vivo macrophage-to-feces reverse cholesterol transport despite increased biliary sterol secretion in mice. J. Lipid Res. 53(3), 348-357 (2012).
103. Ren S, Shen GX. Impact of antioxidants and HDL on glycated LDL-induced generation of fibrinolytic regulators from vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 20(6), 1688-1693 (2000). (Pubitemid 30353906)
104. Matsuki K, Tamasawa N, Yamashita M et al. Metformin restores impaired HDL-mediated cholesterol efflux due to glycation. Atherosclerosis 206(2), 434-438 (2009).
105. Rashduni DL, Rifici VA, Schneider SH, Khachadurian AK. Glycation of high-density lipoprotein does not increase its susceptibility to oxidation or diminish its cholesterol efflux capacity. Metabolism 48(2), 139-143 (1999). (Pubitemid 29072265)
106. Ferretti G, Bacchetti T, Marchionni C, Caldarelli L, Curatola G. Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity. Acta Diabetol. 38(4), 163-169 (2001). (Pubitemid 34145695)
107. Matsunaga T, Iguchi K, Nakajima T et al. Glycated high-density lipoprotein induces apoptosis of endothelial cells via a mitochondrial dysfunction. Biochem. Biophys. Res. Commun. 287(3), 714-720 (2001). (Pubitemid 32912773)
108. Nobecourt E, Davies MJ, Brown BE et al. The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase. Diabetologia 50(3), 643-653 (2007). (Pubitemid 46215509)
109. Lapolla A, Brioschi M, Banfi C et al. Nonenzymatically glycated lipoprotein ApoA-I in plasma of diabetic and nephropathic patients. Ann. N. Y. Acad. Sci. 1126, 295-299 (2008). (Pubitemid 351589268)
110. Suzukawa M, Ishikawa T, Yoshida H, Nakamura H. Effect of in-vivo supplementation with low-dose vitamin E on susceptibility of low-density lipoprotein and high-density lipoprotein to oxidative modification. J. Am. Coll. Nutr. 14(1), 46-52 (1995).
111. Younis NN, Soran H, Charlton-Menys V et al. High density lipoprotein impedes glycation of low density lipoprotein. Diab. Vasc. Dis. Res. doi:10.1177/1479164112454309 (2012) (Epub ahead of print).
112. Ferretti G, Bacchetti T, Marchionni C, Dousset N. Effect of non-enzymatic glycation on aluminium-induced lipid peroxidation of human high density lipoproteins (HDL). Nutr. Metab. Cardiovasc. Dis. 14(6), 358-365 (2004). (Pubitemid 40459258)
113. Bots ML, Visseren FL, Evans GW et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidemia (RADIANCE 2 study): A randomised, double-blind trial. Lancet 370(9582), 153-160 (2007). (Pubitemid 47042895)
114. Briel M, Ferreira-Gonzalez I, You JJ et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: Systematic review and meta-regression analysis. BMJ 338, b92 (2009).
115. Onat A, Can G, Ayhan E, Kaya Z, Hergenc G. Impaired protection against diabetes and coronary heart disease by high-density lipoproteins in Turks. Metabolism 58(10), 1393-1399 (2009).
116. Barter PJ, Rye KA. Cholesteryl ester transfer protein (CETP) inhibition as a strategy to reduce cardiovascular risk. J. Lipid Res. 53(9), 1755-1766 (2012).
117. Corsetti JP, Bakker SJ, Sparks CE, Dullaart RP. Apolipoprotein A-II influences apolipoprotein E-linked cardiovascular disease risk in women with high levels of HDL cholesterol and C-reactive protein. PLoS ONE 7(6), e39110 (2012).
118. Voight BF, Peloso GM, Orho-Melander M et al. Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study. Lancet 380(9841), 572-580 (2012).
119. Yvan-Charvet L, Kling J, Pagler T et al. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler. Thromb. Vasc. Biol. 30(7), 1430-1438 (2010).
120. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98(19), 2088-2093 (1998). (Pubitemid 28512236)
121. Paragh G, Seres I, Harangi M et al. The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease. Diabetes Metab. 29(6), 613-618 (2003). (Pubitemid 38082164)
122. Durrington PN, Mackness MI, Bhatnagar D et al. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in Type IIb hyperlipoproteinaemia. Atherosclerosis 138(1), 217-225 (1998). (Pubitemid 28255170)
123. Rotllan N, Llaverias G, Julve J et al. Differential effects of gemfibrozil and fenofibrate on reverse cholesterol transport from macrophages to feces in vivo. Biochim. Biophys. Acta 1811(2), 104-110 (2011).
124. Phuntuwate W, Suthisisang C, Koanantakul B, Chaloeiphap P, Mackness B, Mackness M. Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels. Atherosclerosis 196(1), 122-128 (2008).
125. Tsimihodimos V, Kakafika A, Tambaki AP et al. Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. J. Lipid Res. 44(5), 927-934 (2003). (Pubitemid 37279653)
126. Yesilbursa D, Serdar A, Saltan Y et al. The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia. Kardiol. Pol. 62(6), 526-530 (2005). (Pubitemid 40961466)
127. Jonker JT, Wang Y, de Haan W et al. Pioglitazone decreases plasma cholesteryl ester transfer protein mass, associated with a decrease in hepatic triglyceride content, in patients with Type 2 diabetes. Diabetes Care 33(7), 1625-1628 (2010).
128. Chappuis B, Braun M, Stettler C et al. Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with Type 2 diabetes mellitus: A prospective, randomized crossover study. Diabetes Metab. Res. Rev. 23(5), 392-399 (2007). (Pubitemid 47091243)
129. Charlton-Menys V, Betteridge DJ, Colhoun H et al. Apolipoproteins, cardiovascular risk and statin response in Type 2 diabetes: The Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 52(2), 218-225 (2009).
130. Guan JZ, Tamasawa N, Murakami H et al. HMG-CoA reductase inhibitor, simvastatin improves reverse cholesterol transport in Type 2 diabetic patients with hyperlipidemia. J. Atheroscler. Thromb. 15(1), 20-25 (2008).
131. Dallinga-Thie GM, van Tol A, Dullaart RP. Plasma pre beta-HDL formation is decreased by atorvastatin treatment in Type 2 diabetes mellitus: Role of phospholipid transfer protein. Biochim. Biophys. Acta 1791(8), 714-718 (2009).
132. Caslake MJ, Stewart G, Day SP et al. Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. Atherosclerosis 171(2), 245-253 (2003). (Pubitemid 37486076)
133. Abdin AA, Hassanien MA, Ibrahim EA, El-Noeman Sel D. Modulating effect of atorvastatin on paraoxonase 1 activity in Type 2 diabetic Egyptian patients with or without nephropathy. J. Diabetes Complications 24(5), 325-333 (2010).
134. Manfredini V, Biancini GB, Vanzin CS et al. Simvastatin treatment prevents oxidative damage to DNA in whole blood leukocytes of dyslipidemic Type 2 diabetic patients. Cell Biochem. Funct. 28(5), 360-366 (2010).
135. Harangi M, Seres I, Varga Z et al. Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage. Eur. J. Clin. Pharmacol. 60(10), 685-691 (2004).
136. Kural BV, Orem C, Uydu HA, Alver A, Orem A. The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia. Coron. Artery Dis. 15(5), 277-283 (2004). (Pubitemid 39061612)
137. Paragh G, Torocsik D, Seres I et al. Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia. Curr. Med. Res. Opin. 20(8), 1321-1327 (2004). (Pubitemid 39120797)
138. Sardo MA, Campo S, Bonaiuto M et al. Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients. Curr. Med. Res. Opin. 21(5), 777-784 (2005). (Pubitemid 40695300)
139. Kim YD, Park KG, Lee YS et al. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes 57(2), 306-314 (2008).
140. Romero IL, McCormick A, McEwen KA et al. Relationship of Type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet. Gynecol. 119(1), 61-67 (2012).
141. Durrington PN. Cholesteryl ester transfere protein (CETP) inhibitors. Lipids (2012) (In Press).
142. Kuivenhoven JA, De Grooth GJ, Kawamura H et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in Type II dyslipidemia. Am. J. Cardiol. 95(9), 1085-1088 (2005). (Pubitemid 40544314)
143. Brousseau ME, Schaefer EJ, Wolfe ML et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. 350(15), 1505-1515 (2004). (Pubitemid 38477775)
144. Schaefer EJ, Asztalos BF. Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction. Curr. Opin. Lipidol. 17(4), 394-398 (2006). (Pubitemid 44079476)
145. Cao G, Beyer TP, Zhang Y et al. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. J. Lipid Res. 52(12), 2169-2176 (2011).
146. Nicholls SJ, Brewer HB, Kastelein JJ et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: A randomized controlled trial. JAMA 306(19), 2099-2109 (2011).
147. Tardif JC, Gregoire J, L'allier PL et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: A randomized controlled trial. JAMA 297(15), 1675-1682 (2007). (Pubitemid 46631626)
148. van Oostrom O, Nieuwdorp M, Westerweel PE et al. Reconstituted HDL increases circulating endothelial progenitor cells in patients with Type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. 27(8), 1864-1865 (2007). (Pubitemid 47207184)
149. Hoang A, Drew BG, Low H et al. Mechanism of cholesterol efflux in humans after infusion of reconstituted high-density lipoprotein. Eur. Heart J. 33(5), 657-665 (2011).
150. Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79(1), 8-15 (1989). (Pubitemid 19043669)